BioLineRx is trading 7.84% up at $3.03, benefiting primarily from a stronger biotechnology sector.
- XBI is up 2.06% during the regular session.
- No new company-specific announcement directly explaining the August 26, 2026 gain was identified.
- Investors are also positioning ahead of BioLineRx’s scheduled second-quarter 2026 results on August 31, 2026, before the U.S. market opens.